
LabPMM®’s NPM1 MRD Assay Gains New York Approval to Guide Treatment and Speed Up Targeted Clinical Trials
Invivoscribe is pleased to announce that the NPM1 MRD Assay developed by its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM), has been approved by the State of New York. This approval comes just two months after the FLT3 ITD MRD Assay was approved…












